Wui-Jin Koh named chief medical officer at NCCN

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Wui-Jin Koh was named to the newly created position of senior vice president and chief medical officer of the National Comprehensive Cancer Network.

Koh is a board-certified radiation oncologist, professor, and medical director for radiation oncology at Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance, an NCCN Member Institution. He specializes in the treatment of gynecologic and gastrointestinal malignancies.

The new CMO role will include overseeing the NCCN Oncology Research Program, which emphasizes collaborative research.

Koh will also help oversee the flagship NCCN Clinical Practice Guidelines in Oncology Guide program. In addition, he will be responsible for medical leadership and oversight for NCCN’s continuing medical education program, and will represent the organization at clinical and scientific meetings.

Koh began contributing his time to NCCN as a founding member of the NCCN Guidelines Panel for Uterine/Cervical Cancer in 1997. He was named panel co-chair in 2004.

His work is an integral part of the ongoing creation of the NCCN Harmonized Guidelines for Sub-Saharan Africa. Koh also served as a member of the pancreatic cancer panel for seven years, and currently sits on the editorial board of the Journal of the National Comprehensive Cancer Network. He is also an editorial board member for Cancer, American Journal of Clinical Oncology, and Gynecologic Oncology Research and Practice, and a former member for Gynecologic Oncology.

Outside of NCCN, Koh has held leadership positions with NRG Oncology (formerly Gynecologic Oncology Group), Western Association of Gynecologic Oncologists, International Society of Gynecologic Cancer, the National Cancer Institute’s Gynecologic Cancer Steering Committee, and the Society of Gynecologic Oncology.

Koh’s official start date will be Oct. 1.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login